FDA Approves At-Home HPV Tests for Cervical Cancer Screening

New self-collection options aim to improve access and convenience, but don't replace comprehensive gynecological care.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

The U.S. Health Resources and Services Administration (HRSA) recently indicated that self-testing for HPV is an option for many, moving away from the traditional requirement of a pelvic exam performed by a clinician. This shift reflects a growing emphasis on patient convenience and expanding access to crucial preventative care. While at-home HPV testing represents a significant step forward, it's not a replacement for comprehensive gynecological care.

Why it matters

Cervical cancer screening is vital, but data shows a substantial proportion of those diagnosed are either unscreened or under-screened. Self-collection tests have the potential to improve screening rates, particularly among those who face barriers to traditional methods. However, a positive result from an at-home test typically necessitates a follow-up examination with a healthcare provider.

The details

The FDA initially approved HPV tests allowing for self-collection in healthcare settings on May 14, 2024. The introduction of the first FDA-approved at-home self-collection cervical cancer screening kit, the Teal Wand, in January 2026, further expands access to screening. This new guidance builds on recommendations issued by the U.S. Preventive Services Task Force (USPSTF) in January 2025, which advocated for self-collected HPV testing as a viable option for cervical cancer screening.

  • The FDA initially approved HPV tests allowing for self-collection in healthcare settings on May 14, 2024.
  • The first FDA-approved at-home self-collection cervical cancer screening kit, the Teal Wand, was introduced in January 2026.
  • The U.S. Preventive Services Task Force (USPSTF) issued recommendations advocating for self-collected HPV testing as a viable option for cervical cancer screening in January 2025.

The players

HRSA

The U.S. Health Resources and Services Administration, which recently indicated that self-testing for HPV is an option for many, moving away from the traditional requirement of a pelvic exam performed by a clinician.

Jeanne Conry

An ob-gyn and former chair of the Women's Preventive Services Initiative, who points out that if we see ourselves only as the Pap smear specialists, we have failed patients.

Amanda Bruegl

A gynecologic oncologist at the Oregon Health and Science University School of Medicine, who explains that women in their 20s, when HPV infections are common, should prioritize regular screenings.

Colleen Denny

An ob-gyn based in New York and a fellow of the American College of Obstetricians and Gynecologists, who notes that a well-woman visit extends far beyond a Pap smear.

Got photos? Submit your photos here. ›

What they’re saying

“If we see ourselves only as the Pap smear specialists, we have failed [patients].”

— Jeanne Conry, Ob-gyn and former chair of the Women's Preventive Services Initiative

“We have 20 minutes to talk about all the things that have happened to you in your reproductive life all year. It's great that we don't have to wedge a Pap smear into there also.”

— Colleen Denny, Ob-gyn and fellow of the American College of Obstetricians and Gynecologists

“Someone should be talking about all the [other] basic health screenings, all the basic wellness things, every single year.”

— Amanda Bruegl, Gynecologic oncologist

What’s next

The FDA is expected to continue approving more at-home HPV testing options to further expand access to cervical cancer screening.

The takeaway

While at-home HPV testing offers a more convenient and accessible option for cervical cancer screening, it should not replace comprehensive gynecological care. Regular visits with an ob-gyn provide essential health assessments and consultations beyond just Pap smears.